Invex TherapeuticsASX:IXC -10.00% Net Current Asset Value is A$0.06 as of Dec. 2025, which is 100% below its 10-year median of 1.47. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Invex Therapeutics ranks better than 82.56% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Invex Therapeutics's net current asset value per share for the quarter that ended in Dec. 2025 was A$0.06.
The historical rank and industry rank for Invex Therapeutics's Net Current Asset Value or its related term are showing as below:
ASX:IXC'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.71 Med: 1.47 Max: 4.53
Current: 1.5
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Invex Therapeutics was 4.53. The lowest was 0.71. And the median was 1.47.
ASX:IXC's Price-to-Net-Current-Asset-Value is ranked better than 82.56% of 946
companies
in the Biotechnology industry
Industry Median: 4.76
vs ASX:IXC: 1.50
Invex Therapeutics (ASX:IXC) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Invex Therapeutics Net Current Asset Value Related Terms
Invex Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IXC vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Invex Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.06 mean?
Invex Therapeutics (ASX:IXC) has a Net Current Asset Value of A$0.06 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Invex Therapeutics and its competitors. This is 96% below median its historical median of 1.47. Over the past decade, Invex Therapeutics' Net Current Asset Value has ranged from 0.71 to 4.53. According to the industry distribution chart, Invex Therapeutics ranks #165 out of 946 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Invex Therapeutics' Net Current Asset Value too high?
Invex Therapeutics' current Net Current Asset Value of A$0.06 is 96% below median its 10-year median of 1.47. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 4.53. Based on the distribution chart, Invex Therapeutics ranks #165 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Invex Therapeutics' Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #165 out of 946 companies for Net Current Asset Value. This places Invex Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.76. Historically, Invex Therapeutics' own Net Current Asset Value has ranged from 0.71 to 4.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.76, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Invex Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current Net Current Asset Value is A$0.06, which is 96% below median its own 10-year median of 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Net Current Asset Value of A$0.06. The current Net Current Asset Value is A$0.06, which is 96% below median its 10-year median of 1.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Net Current Asset Value is A$0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 